Does Myriad alter the patentability of natural products?

1 min

Robert Schwartz and Leslie Kushner examine whether the ruling of the Supreme Court case, Association of Molecular Pathology v. Myriad Genetics, Inc. , — finding that a naturally occurring DNA sequence is a product of nature that is not patent eligible — is narrowly applicable only to nucleic acids or will be broadly interpreted to apply to all naturally occurring biomolecules.